![Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/87f2f292-a23c-443e-8613-f525f0cc11ff/gr2_lrg.jpg)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet
Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label ext
![Patient disposition in IBD in the NOR-SWITCH main and extension study.... | Download Scientific Diagram Patient disposition in IBD in the NOR-SWITCH main and extension study.... | Download Scientific Diagram](https://www.researchgate.net/publication/344370616/figure/fig1/AS:977375575670785@1610035904552/Patient-disposition-in-IBD-in-the-NOR-SWITCH-main-and-extension-study-CD-Crohns_Q640.jpg)
Patient disposition in IBD in the NOR-SWITCH main and extension study.... | Download Scientific Diagram
![Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/9522bb73-f6c9-43bf-8515-062ea097145a/gr2.jpg)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet
![Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/ace666d3-c23d-4a2b-ab30-d3789142dd66/gr1_lrg.gif)